Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).
From Alembic Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4).
- US branded specialty business projected to scale up over next few quarters and start contributing positively to profit from FY28 onwards (Pages 6,14).
- Around 15 new product launches planned in the US in next 9 months, with a similar number expected next year, supporting sustained US growth (Page 13).
- ROW (Rest of World) markets expected to achieve around 15% growth in INR terms in FY27, with potential to surpass this depending on market conditions (Page 14).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
- Preventive debottlenecking and maintenance upgrades were done in facilities (e.g., Ophthaline) to expand capacity without incremental capex.
- Strategic investments ongoing in R&D, manufacturing capabilities, and US branded business platform.
- Investments in US branded platform focus on building commercial capabilities and scaling specialty franchises; primarily marketing and field force costs with no manufacturing asset investments.
- Working on peptide development, regulatory filings, and portfolio development initiatives as part of R&D capital.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q1 FY27 results?
US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.3 with a market cap of ₹16,624 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.